XML 52 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
Agreement
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Agreement
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue $ 188,411 $ 133,791 $ 318,935 $ 275,710  
AstraZeneca [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Number of collaboration agreements | Agreement 2   2    
Revenue $ 59,501 $ 17,768 $ 83,926 $ 37,611  
Deferred revenue $ 0   $ 0   $ 0
AstraZeneca [Member] | Revenue [Member] | Strategic Partner [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Concentration percentage 32.00% 13.00% 26.00% 14.00%  
AstraZeneca [Member] | Maximum [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Cumulative payments received $ 610,000   $ 610,000    
Eplontersen Collaboration [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Number of collaboration agreements | Agreement 1   1    
Revenue $ 20,000        
Eplontersen Collaboration [Member] | Maximum [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Next payment to be achieved $ 50,000   $ 50,000    
Cardiovascular, Renal and Metabolic Diseases Collaboration [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Number of collaboration agreements | Agreement 1   1    
Cardiovascular, Renal and Metabolic Diseases Collaboration [Member] | Maximum [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Next payment to be achieved $ 30,000   $ 30,000    
Cardiovascular, Renal and Metabolic Diseases Collaboration [Member] | ION839 [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue $ 20,000